izpis_h1_title_alt

Non-animal glioblastoma models for personalized treatment
ID Zottel, Alja (Avtor), ID Jovchevska, Ivana (Avtor), ID Šamec, Neja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (2,11 MB)
MD5: 0FE6347909E948C36AB99DF4CCE276BC
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S2405844023082786 Povezava se odpre v novem oknu

Izvleček
Glioblastoma is an extremely lethal cancer characterized by great heterogeneity at different molecular and cellular levels. As a result, treatment options have moved far from systemic and universal therapies toward targeted treatments and personalized medicine. However, for successful translation from preclinical studies to clinical trials, experiments must be performed on reliable disease models. Numerous experimental models have been developed for glioblastoma, ranging from simple 2D cell cultures to study the nature of the disease to complex 3D models such as neurospheres, organoids, tissue-slice cultures, bioprinted models, and tumor on chip, as perfect prototypes to evaluate the therapeutic potential of different drugs. The presence of multiple research models is consistent with the complexity and molecular diversity of glioblastoma. The advantage of such models is the recapitulation of the tumor environment, and in some cases the preservation of immune system components as well as the creation of simple vessels. There are also two case studies translating in vitro studies on glioblastoma organoids to patients as well as four ongoing clinical trials using glioblastoma models, indicating high clinical potential of glioblastoma models.

Jezik:Angleški jezik
Ključne besede:glioblastoma, heterogeneity, non-animal models, treatmet predicition
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:9 str.
Številčenje:Vol. 9, iss. 10, art. e21070
PID:20.500.12556/RUL-152948 Povezava se odpre v novem oknu
UDK:616-006:577.2
ISSN pri članku:2405-8440
DOI:10.1016/j.heliyon.2023.e21070 Povezava se odpre v novem oknu
COBISS.SI-ID:170364419 Povezava se odpre v novem oknu
Datum objave v RUL:13.12.2023
Število ogledov:372
Število prenosov:31
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Heliyon
Založnik:Elsevier
ISSN:2405-8440
COBISS.SI-ID:21607432 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:glioblastom, heterogenost, neživalski modeli, napoved zdravljenja

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-2649
Naslov:Določitev novih biomarkerjev glioblastoma za namen neinvazivne tekočinske biopsije

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-4510
Naslov:Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma, pripravljene iz tkiva bolnikov

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0390
Naslov:Funkcijska genomika in biotehnologija za zdravje

Financer:Drugi - Drug financer ali več financerjev
Program financ.:CELSA
Naslov:Generation of nanobodies against immunomodulating checkpoint receptors in glioblastoma tumor cells

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj